Clinical Trials Browser

Phase 1/2 × dostarlimab × Gynecologic × Clear all

NCT05559879 2025-05-04

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

Phase 1/2 Recruiting

Carcinoma, Uterine Neoplasms, Endometrial Neoplasms

NCT06385548 2025-04-01

LiDer

Phase 1/2 Withdrawn

Endometrial Neoplasms